Below are the financial statements of Denali Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Collaboration revenue | — | — | — |
| Collaboration revenue from customers | 0a | 330.53a | 105.07a |
| Other collaboration revenue | 0a | 0a | 3.4a |
| Total collaboration revenue | 0a | 330.53a | 108.46a |
| Operating expenses | — | — | — |
| Research and development | -396.44a | -423.88a | -358.73a |
| General and administrative | -105.44a | -103.35a | -90.48a |
| Total operating expenses | -501.88a | -527.23a | -449.21a |
| Gain from divestiture of small molecule programs | 14.54a | 0a | 0a |
| Loss from operations | -487.34a | -196.7a | -340.74a |
| Interest and other income, net | 64.64a | 51.51a | 14.77a |
| Loss before income taxes | -422.71a | -145.19a | -325.97a |
| Income tax expense | -0.07a | -0.03a | -0.02a |
| Net loss | -422.77a | -145.22a | -325.99a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Denali Therapeutics’s data sources below and access millions more through our Disclosure Search.